Bimekizumab 3-year maintenance of response in Week 16 responders with moderate to severe plaque psoriasis: Results from five phase 3/3b trials

Objective

To report maintenance of response over 3 years in patients who achieved complete or near-complete skin clearance after 16 weeks of bimekizumab (BKZ) treatment from five phase 3/3b trials.

Introduction

- BKZ, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A,¹ has demonstrated rapid and superior efficacy in the treatment of patients with moderate to severe plaque psoriasis in head-to-head studies versus ustekinumab, adalimumab, and secukinumab, with established long-term durability of response.²⁻⁶
- As psoriasis is a chronic disease and loss of response to therapies can occur over time, studying long-term efficacy of new treatments is important.⁷
- Maintenance of responses through 3 years of BKZ 320 mg treatment, in psoriasis patients who achieved disease control after 16 weeks, has been shown previously in patients from four phase 3 trials.^e
- Here, we report maintenance of response from the largest available data pool through 3 years, with patients included across five phase 3/3b trials.

Methods

- Data were pooled from the 52-week BE VIVID, 56-week BE READY, and 56-week BE SURE phase 3 trials, their ongoing open-label extension (OLE), BE BRIGHT, as well as the BE RADIANT phase 3b trial (48-week double-blinded period, 96-week OLE; Figure 1).²⁻⁶
- Included patients were randomised to BKZ 320 mg every 4 weeks (Q4W) at baseline to Week 16. Patients then received either BKZ Q4W or every 8 weeks (Q8W) through the maintenance and OLE periods.
- All patients still receiving BKZ Q4W were re-assigned to BKZ Q8W at OLE Week 16/48 (BE RADIANT/BE BRIGHT) or next scheduled visit, via protocol amendment.
- Maintenance of ≥90/100% improvement from baseline in Psoriasis Area and Severity Index (PASI 90/100), and Investigator's Global Assessment (IGA) 0/1 responses through Year 3 (Week 144/OLE Week 96) are reported in Week 16 PASI 90, PASI 100, and IGA 0/1 responders, respectively
- Dermatology Life Quality Index (DLQI) 0/1 responses (indicating no impact of skin disease on patient's life)⁸ are also reported in Week 16 PASI 100 responders.
- Data are reported for the combined BKZ dosing groups (BKZ Total) and for the subset of patients who received BKZ Q4W/Q8W/Q8W (initial/maintenance/OLE) dosing.
- Data are reported using modified non-responder imputation (mNRI): patients who discontinued due to lack of efficacy or treatment-related adverse events were considered non-responders at subsequent timepoints; multiple imputation was used for all other missing data (NRI/observed case [OC] data in Table 2 only)

Results

- Across the phase 3/3b trials, 1,362 patients were randomised to BKZ Q4W for the initial treatment periods
- Among these, 86.9% achieved PASI 90, 62.4% achieved PASI 100, and 86.9% achieved IGA 0/1 at Week 16 (Figure 2). 995 PASI 90 responders, 719 PASI 100 responders, and 985 IGA 0/1 responders entered the OLE
- Baseline characteristics of these patients are presented in Table 1.
- Among Week 16 PASI 90, PASI 100, and IGA 0/1 responders, 96.0%, 88.7%, and 95.8% maintained their responses at Year 1 (Week 48; Figure 2A–C; Table 2).
- Among Week 16 PASI 100 responders, DLQI 0/1 response rates increased through the first year of BKZ treatment, with 89.1% achieving DLQI 0/1 at Year 1 (Figure 2D).
- These high levels of response continued to be sustained up to Year 3 (Week 144; Figure 2; Table 2).
- Similarly high responses were maintained over 3 years in Week 16 responders who received BKZ Q4W/Q8W/Q8W (Figure 2; Table 2)
- Study discontinuation in Week 16 PASI 90, PASI 100, and IGA 0/1 responders due to loss of efficacy and adverse events during the maintenance period and OLE was low (n=8/1,102 [0.7%] and n=77/1,102 [7.0%], respectively).

Conclusions

Pooled data from five trials found that, among Week 16 responders, high clinical responses were maintained through 3 years of BKZ 320 mg treatment. High levels of response were also maintained in those who received BKZ Q4W/Q8W/Q8W, the approved dosing regimen for most patients with psoriasis.9

Summary





Table 1 Baseline characteristics

	Week 16 PASI 90 responders		Week 16 PASI 100 responders		Week 16 IGA 0/1 respon	
	BKZ Total (N=995)	BKZ Q4W/ Q8W/Q8W (N=348)	BKZ Total (N=719)	BKZ <mark>Q4W/</mark> Q8W/Q8W (N=267)	BKZ Total (N=985)	BK Q8 (N
Age (years), mean ± SD	45.0 <u>+</u> 13.5	44.8 <u>+</u> 14.1	45.1 <u>+</u> 13.3	44.5 <u>+</u> 13.8	45.1 <u>+</u> 13.5	45.
Male , n (%)	695 (69.8)	247 (71.0)	497 (69.1)	185 (69.3)	692 (70.3)	24
White , n (%)	872 (87.6)	330 (94.8)	642 (89.3)	254 (95.1)	871 (88.4)	32
Weight (kg), mean <u>+</u> SD	89.1 <u>+</u> 20.8	88.9 <u>+</u> 20.7	87.9 <u>+</u> 19.6	87.4 <u>+</u> 19.0	89.4 <u>+</u> 20.8	88
Duration of psoriasis (years) , mean <u>+</u> SD	18.2 <u>+</u> 12.6	18.6 <u>+</u> 12.4	18.2 <u>+</u> 12.6	19.2 <u>+</u> 12.8	18.3 <u>+</u> 12.5	19.
PASI, mean <u>+</u> SD	21.2 <u>+</u> 7.7	20.6 <u>+</u> 7.5	20.8 ± 7.3	20.4 <u>+</u> 7.4	21.0 <u>+</u> 7.6	20
BSA (%) , mean <u>+</u> SD	26.9 <u>+</u> 16.0	24.5 <u>+</u> 13.6	25.8 ± 15.0	23.8 ± 13.2	26.5 <u>+</u> 15.7	24.
IGA , n (%)						
3: moderate	652 (65.5)	240 (69.0)	476 (66.2)	181 (67.8)	648 (65.8)	23
4: severe	341 (34.3)	107 (30.7)	242 (33.7)	86 (32.2)	334 (33.9)	10
DLQI total score, mean ± SD	10.7 <u>+</u> 6.4	10.7 <u>+</u> 6.3	10.9 <u>+</u> 6.5	10.9 <u>+</u> 6.4	10.7 <u>+</u> 6.4	10
Any prior systemic therapy, n (%)	772 (77.6)	266 (76.4)	568 (79.0)	209 (78.3)	760 (77.2)	26
Prior biologic therapy , n (%)	383 (38.5)	125 (35.9)	282 (39.2)	98 (36.7)	378 (38.4)	12

Data were pooled for all patients who were randomised to BKZ at the start of the study in BE SURE, BE READY, BE VIVID, and BE RADIANT, achieved a PASI 90, PASI 100, or IGA 0/1 response, respectively, at Week 16 and entered the relevant OLE (BKZ Total). Data are also presented for the subsets of these patients who received BKZ Q4W during the initial treatment periods, BKZ Q8W during the maintenance treatment periods and BKZ Q8W during the OLE periods (the approved dosing regimen for the majority of patients). The BE VIVID study design did not include a Q4W/Q8W/Q8W treatment arm, therefore patients from BE VIVID are not included in the Q4W/Q8W/Q8W subset.

SD: standard deviation

References: ¹Adams R et al. Front Immunol 2020;11:1894; ²Reich K et al. N Engl J Med 2021;385:142–52, NCT03370133; ³Gordon KB et al. D ancet 2021;397:475–86, NCT03410992; ⁴Warren RB et al. N Engl J Med 2021;385:142–52, NCT03536884; ⁶Strober B et al. D ancet 2021;397:475–86, NCT03410992; ⁴Warren RB et al. N Engl J Med 2021;385:142–52, NCT03370133; ³Gordon KB et al. Br J Dermatol 2023;188:749–597, NCT03598790; ⁷Warren RB et al. N Engl J Med 2021;385:142–52, NCT03536884; ⁶Strober B et al. Br J Dermatol 2023;188:749–507, NCT03598790; ⁷Warren RB et al. N Engl J Med 2021;385:142–52, NCT03536884; ⁶Strober B et al. Br J Dermatol 2023;188:749–507, NCT03598790; ⁷Warren RB et al. N Engl J Med 2021;385:142–52, NCT03598790; ⁷Warren RB et al. N Engl J Med 2021;385 3. Available at: https://www.ema.europ tion_en.pdf [Accessed September 2023]. Author Contributions: Substantial contributions to study conception/design, or acquisition/analysis/interpretation of data: DT, AA, KBG, AB, CP, WHB, MW, BS, BH, JL, ML; Drafting of the publication, or revising it x-epar-productritically for important intellectual content: DT, AA, KBG, AB, CP, WHB, MW, BS, BH, JL, ML; Final approval of the publication: DT, AA, KBG, AB, CP, WHB, MW, BS, BH, JL, ML; Final approval of the publication: DT, AA, KBG, AB, CP, WHB, MW, BS, BH, JL, ML; Final approval of the publication: DT, AA, KBG, AB, CP, WHB, MW, BS, BH, JL, ML; Final approval of the publication: DT, AA, KBG, AB, CP, WHB, MW, BS, BH, JL, ML; Final approval of the publication: DT, AA, KBG, AB, CP, WHB, MW, BS, BH, JL, ML; Final approval of the publication: DT, AA, KBG, AB, CP, WHB, MW, BS, BH, JL, ML; Final approval of the publication: DT, AA, KBG, AB, CP, WHB, MW, BS, BH, JL, ML; Final approval of the publication: DT, AA, KBG, AB, CP, WHB, MW, BS, BH, JL, ML; Final approval of the publication: DT, AA, KBG, AB, CP, WHB, MW, BS, BH, JL, ML; Final approval of the publication: DT, AA, KBG, AB, CP, WHB, MW, BS, BH, JL, ML; Final approval of the publication: DT, AA, KBG, AB, CP, WHB, MW, BS, BH, JL, ML; Final approval of the publication: DT, AA, KBG, AB, CP, WHB, MW, BS, BH, JL, ML; Final approval of the publication: DT, AA, KBG, AB, CP, WHB, MW, BS, BH, JL, ML; Final approval of the publication: DT, AA, KBG, AB, CP, WHB, MW, BS, BH, JL, ML; Final approval of the publication: DT, AA, KBG, AB, CP, WHB, MW, BS, BH, JL, ML; Final approval of the publication: DT, AA, KBG, AB, CP, WHB, MW, BS, BH, JL, ML; Final approval of the publication: DT, AA, KBG, AB, CP, WHB, MW, BS, BH, JL, ML; Final approval of the publication: DT, AA, KBG, AB, CP, WHB, MW, BS, BH, JL, ML; Final approval of the publication: DT, AA, KBG, AB, CP, WHB, MW, BS, BH, JL, ML; Final approval of the publication: DT, AA, KBG, AB, CP, WHB, MW, BS, AB, CP, WHB, MW, AS, AB, CP, WH Target-Solution and UCB Pharma, Bristol Myers Squibb, Celgene, Dermina, Eli Lilly, Pharma, and Novartis, ALS Paret as a research investigator and/or solution, and UCB Pharma, and Novartis, Als Served as a research investigator and/or solution, and UCB Pharma, and Novartis, Als Served as a research investigator and/or solution, and UCB Pharma, and Novartis, Als Served as a research investigator and/or solution, and UCB Pharma, Bristol Myers Squibb, Celgene, Dermina, Eli Lilly, El, Ans. Served as a research investigator and/or solution. Als Served as a rese Almirall, Alumis, Amgen, Anaptysbio, Apogee, Arcutis, Arena, Aslan, Athenex, Bluefin Biomedicine, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, CTI BioPharma, Merck, Monte Rosa therapeutics, Pfizer, Rani, Rapt, Regeneron, Sanofi, Genzyme Spheri Global Insights, Sun Pharma, Takeda, TLL Pharmaceutical, TrialSpark, UCB Pharma, Union, Ventyx, Vibliome and Xencor; clinical study investigator (institution has received clinical study funds) for AbbVie, Acelyrin, Allakos, Almirall, Alumis, Amgen, Arcutis, Athenex, Boehringer Ingelheim, Bristol Myers Squibb, Concert, Dermavant, Eli Lilly, Evelo, Evommune, Galderma, Incyte, Janssen, LEO Pharma, Merck, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharma UCB Pharma, and Ventyx. CP: Received consulting fees and/or grants from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Celgene, GSK, Janssen, LEO Pharma, WHB: Received honoraria as a speaker and/or advisor from AbbVie, Almirall, Bristol Myers Squibb, Eli Lilly, Janssen, LEO Pharma, Novartis, and UCB Pharma, Novartis, and UCB Pharma, Eli Lilly, Novartis, Pierre Fabre, Pfizer, Sanofi-Regeneron, and UCB Pharma, Eli Lilly, Novartis, Pierre Fabre, Pfizer, Sanofi-Regeneron, and UCB Pharma, WHB: Received honoraria as a speaker and/or advisor from AbbVie, Almirall, Bristol Myers Squibb, Eli Lilly, Janssen, LEO Pharma, Eli Lilly, Novartis, and UCB Pharma, Eli Lilly, Novartis, Pierre Fabre, Pfizer, Sanofi-Regeneron, and UCB Pharma, Eli Lilly, Novartis, Pierre Fabre, Pfizer, Sanofi-Regeneron, and UCB Pharma, Eli Lilly, Novartis, Pierre Fabre, Pfizer, Sanofi-Regeneron, and UCB Pharma, Eli Lilly, Novartis, Pierre Fabre, Pfizer, Sanofi-Regeneron, and UCB Pharma, Eli Lilly, Novartis, Pierre Fabre, Pfizer, Sanofi-Regeneron, and UCB Pharma, Eli Lilly, Novartis, Pierre Fabre, Pfizer, Sanofi-Regeneron, and UCB Pharma, Eli Lilly, Novartis, Pierre Fabre, Pfizer, Sanofi-Regeneron, and UCB Pharma, Eli Lilly, Novartis, Pierre Fabre, Pfizer, Sanofi-Regeneron, and UCB Pharma, Eli Lilly, Novartis, Pierre Fabre, Pfizer, Sanofi-Regeneron, and UCB Pharma, Eli Lilly, Novartis, Pierre Fabre, Pfizer, Sanofi-Regeneron, and UCB Pharma, Eli Lilly, Novartis, Pierre Fabre, Pfizer, Sanofi-Regeneron, and UCB Pharma, Eli Lilly, Novartis, Pierre Fabre, Pfizer, Sanofi-Regeneron, and UCB Pharma, Eli Lilly, Novartis, Pierre Fabre, Pfizer, Sanofi-Regeneron, and UCB Pharma, Eli Lilly, Novartis, Pierre Fabre, Pfizer, Sanofi-Regeneron, and UCB Pharma, Eli Lilly, Novartis, Pierre Fabre, Pfizer, Sanofi-Regeneron, and UCB Pharma, Eli Lilly, Novartis, Pierre Fabre, Pfizer, Sanofi-Regeneron, and UCB Pharma, Eli Lilly, Novartis, Pierre Fabre, Pfizer, Sanofi-Regeneron, and UCB Pharma, Eli Lilly, Novartis, Pierre Fabre, Pfizer, Sanofi-Regeneron, and Pharma, Eli Lilly ML: Employee of Mount Sinai and receives research funds from AbbVie, Amgen, Josef and Receives research funds from AbbVie, Amgen, Acutis, Avotres, Boehringer Ingelaim, Bristol Nyer, Sculbb, Castle Biosciences, Celltrion, Corp Dermavant Sciences, EPI, Evommune Inc., Facilitation of International Dermatology, Galderma, Mindera, Pfizer, Seanergy, Strata, Trevi and Verrica. Acknowledgements: These studies were funded by UCB Pharma. We thank the patients and their caregivers in addition to the investigators and their teams who utics, Brickell Biotech, Boehringer Ingelheim, Bristol Myers Squibb, Castle Biosciences, Celltrion, CorEvita contributed to these studies. The authors acknowledge Joe Dixon, PhD, UCB Pharma, Slough, UK and Susanne Wiegratz, MSc, UCB Pharma, Monheim, Germany for publication coordination, Sana Yaar, PhD, Costello Medical, Manchester, UK for medical writing and editorial assistance and the Creative team at Costello Medical for graphic design assistance. All costs associated writh development of this poster were funded by UCB Pharma.

Diamant Thaçi,¹ April Armstrong,² Kenneth B. Gordon,³ Andrew Blauvelt,⁴ Carle Paul,⁵ Wolf-Henning Boehncke,⁶ Maggie Wang,⁷ Balint Szilagyi,⁸ Bengt Hoepken,⁸ Jérémy Lambert,⁹ Mark Lebwohl¹⁰



Figure 1 Study design (included patients)



Data were pooled for all patients who were randomised to BKZ at the start of the study in BE SURE, BE READY, BE VIVID, and BE RADIANT, achieved a PASI 90. ASI 100, or IGA 0/1 response, respectively, at Week 16 and entered the relevant OLE (BKZ Total). Data are also prese nted for the subsets of these patients wh received BKZ Q4W during the initial treatment periods, BKZ Q8W during the maintenance treatment periods and BKZ Q8W during the OLE periods. Year 1 data were recorded at Week 48, the last common timepoint for PASI, IGA, and DLQI assessment across BE VIVID, BE READY, BE SURE, and BE RADIANT before LE entry. Year 2 refers to Week 96, and Year 3 refers to Week 144. DLQI assessment was performed on a different schedule in BE VIVID compared to BE SURE, BE READY, and BE RADIANT: this table only presents DLQI responses at visits common to BE SURE, BE READY, and BE RADIANT

As this analysis only includes patients randomised to receive BKZ at baseline, only BKZ-randomised patients are included in this study design. BKZ-treated patient who were re-randomised to placeho at Week 16 in BE READY (n=105) were not included in the final analyses reported below, however they are included in the final analyses reported below, however they are included in the national analyses reported below. However they are included in the national analyses reported below. The second Week 48: BE VIVID: Week 52; BE READY and BE SURE: Week 56) were randomised 1:1 in BE RADIANT and 4:1 in BE BRIGHT to BKZ 320 mg Q4W or Q8W; patients ving BKZ 320 mg Q8W who achieved ≥PASI 90 at the end of the feeder studies remained on Q8W dosing; ^bIn BE RADIANT, at OLE Week 16 or the next cheduled clinic visit, all patients switched to BKZ Q8W after the implementation of a protocol amendment; in BE BRIGHT, at OLE Week 24, patients achieving 2PASI 90 could switch to Q8W at the investigator's discretion, and all patients were re-assigned to BKZ Q8W at OLE Week 48 or the next scheduled visit via protocol amendment; COLE Week 48 (the end of Year 2) corresponds to BE RADIANT Week 96, BE VIVID/BE BRIGHT Week 100, and BE READY/BE BRIGHT and BE SURE/BE BRIGHT Week 104; ^dOLE Week 96 (the end of Year 3) corresponds to BE RADIANT Week 144, BE VIVID/BE BRIGHT Week 148, and BE READY/ RIGHT and BE SURE/BE BRIGHT Week 152

Maintenance of PASI 90, PASI 100, IGA 0/1, and DLQI 0/1 in Week 16 BKZ-treated responders who entered the BE BRIGHT or Figure 2 **BE RADIANT OLEs (mNRI)**



P2540

OLE Week 96 (Week 144/148/152) Year

88 96 104 112 120 128 136 14

89.9% 87.1%



scan the QR code or visi Poster ID: P2540 Link expiration: 28 October 202